Cargando…

1606. Distinct Effectiveness of Oritavancin Against Tolerance-Induced Staphylococcus aureus

BACKGROUND: Within a sufficiently large bacterial population, some members will naturally adopt an alternate, metabolically-active state that favors small molecule synthesis over cell division. In Staphylococcus aureus this process can be sharply accelerated by multiple factors present during infect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harven, Lauren, Bingley, Victoria, Berti, Andrew David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778182/ http://dx.doi.org/10.1093/ofid/ofaa439.1786

Ejemplares similares

Distinct Effectiveness of Oritavancin against Tolerance-Induced Staphylococcus aureus
por: Berti, Andrew D., et al.
Publicado: (2020)

Antimicrobial Efficacy against Antibiotic-Tolerant Staphylococcus aureus Depends on the Mechanism of Antibiotic Tolerance
por: Meredith, Emily M., et al.
Publicado: (2022)

327. Oritavancin Activity against Staphylococcus aureus Isolates Causing Bone and Joint Infections in European Hospitals (2010–2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

307. Rapid Resistance Development to Three Antistaphylococcal Therapies in Daptomycin-tolerant Staphylococcus aureus Bacteremia
por: Miller, Christopher R, et al.
Publicado: (2020)

1190. Dual-Plasmid Technology for Precision Genome Editing in Staphylococcus aureus
por: Reish, Jennifer, et al.
Publicado: (2020)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

1812. Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Skin Structure Infections in US Medical Centers between 2017–2019 and 2022
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

P1606: CENTRAL VEIN CATHETERISATION IN ONCOHEMATOLOGICAL PATIENTS: COMPLICATION, ASSOCIATED WITH PROCEDURA AND CARE
por: Romanenko, N.
Publicado: (2022)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

Evolution of Antibiotic Tolerance During Oxacillin, Daptomycin and Dalbavancin Therapy Results in Breakthrough Staphylococcus aureus Bacteremias
por: Berti, Andrew, et al.
Publicado: (2017)

1606 Obesity and Weight Misperception are Common in HIV Positive Patients
por: Karki, Niraj, et al.
Publicado: (2014)

1194. Identification and Characterization of Extracellular Inducers of Persistence in Staphylococcus epidermidis and Staphylococcus aureus
por: Habtu, Danni Y, et al.
Publicado: (2020)

596. Distinct, Segregated Daptomycin-Susceptible and Daptomycin-Nonsusceptible Staphylococcus aureus Populations Associated with Tricuspid-Valve Infective Endocarditis
por: Miller, Christopher R, et al.
Publicado: (2019)

1606. Dual Trajectories of Antiretroviral Therapy Adherence and Polypharmacy in Women with HIV in the United Sate
por: SAEED, A B U B A K E R, et al.
Publicado: (2023)

1420. Successful Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

1606. Legionellosis Cluster Associated with Direct and Indirect Hot Tub Exposure—West Virginia, 2018
por: Rispens, Jared R, et al.
Publicado: (2019)

The economic mind in American civilization, 1606-1865
por: Dorfman, Joseph, 1904-1991
Publicado: (1946)

1629. Vancomycin Resistance in Enterococcus faecium Clinical Isolates Responsible for Bloodstream Infections in US Hospitals Over Ten Years (2010-2019) and Activity of Oritavancin
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

1255. In Vitro Activity of Vancapticin against Methicillin-Resistant Staphylococcus aureus from Periprosthetic Joint Infection
por: Cho, Hye-Kyung, et al.
Publicado: (2020)

Cholecystokinin protects rats against Staphylococcus aureus-induced sepsis
por: Saia, RS, et al.
Publicado: (2012)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

117. Adjunctive Daptomycin in the Treatment of staphylococcus Aureus Bacteremia
por: Cheng, Matthew P, et al.
Publicado: (2020)

1845. Oritavancin Compared to the Standard-of-Care for the Treatment of Gram-positive Blood Stream Infections
por: Moenster, Ryan P, et al.
Publicado: (2022)

269. Clinical Characteristics and Outcomes of Persistent Staphylococcus aureus Bacteremia
por: Yang, Eunmi, et al.
Publicado: (2020)

1320. In Vitro Activity of Lefamulin against Staphylococcus aureus Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis
por: Sader, Helio S, et al.
Publicado: (2021)

282. Epidemiological Evaluation of Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin-Susceptible Staphylococcus aureus (MSSA) Bacteremia: A Comprehensive Cancer Center’s 10-Year Experience
por: Ford, Charles R, et al.
Publicado: (2020)

Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016)
por: Pfaller, Michael A, et al.
Publicado: (2017)

646. Activity of Oritavancin and Comparator Agents Against Coagulase-negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2022)

309. The Impact of Addiction Medicine Consultation on Discharges Against Medical Advice in Patients with Opioid Use Disorder and Staphylococcus Aureus Bacteremia
por: Spivack, Stephanie, et al.
Publicado: (2020)

850. External Validation of the Methicillin-Resistant Staphylococcus aureus Bacteremia Score
por: Boyle, Ellen, et al.
Publicado: (2020)

P1606: PRIMARY AND SECONDARY IMMUNE THROMBOCYTOPENIA (ITP) IN ADULTS: REAL WORLD COMPARATIVE RETROSPECTIVE STUDY FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY
por: Stavroulaki, Emily, et al.
Publicado: (2023)

275. Comparison of Cefazolin versus Nafcillin for Methicillin-Susceptible Staphylococcus aureus Bacteremia with a Deep-Seated Source
por: Mersinger, Katherine E, et al.
Publicado: (2020)

1015. Real World Use of Dalbavancin and Oritavancin for Optimized Outpatient Antimicrobial Therapy in Patients Inappropriate for Standard Therapy
por: Weichman, Brittani, et al.
Publicado: (2022)

1264. Assessment of In Vivo Efficacy of CF-296 in addition to Vancomycin (VAN) and Daptomycin (DAP) against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model
por: Asempa, Tomefa E, et al.
Publicado: (2020)

1059. In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-resistant Subsets
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

1240. Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020
por: Duncan, Leonard R, et al.
Publicado: (2021)

734. Trend Analysis of Oritavancin and Comparator Agents Activity against Enterococcus Causing Infections in US Medical Centers between 2017–2019 and 2022
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

443. The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin for Treatment of Gram-Positive Infections
por: Redell, Mark, et al.
Publicado: (2019)

263. An Evaluation of Quality Indicators for the Management of Staphylococcus aureus Bacteremia: A Nested Case-Control Study
por: Simms, Andrew, et al.
Publicado: (2020)

292. Impact of the BACT/ALERT VIRTUO blood culture system in the management of Staphylococcus aureus bacteremia
por: Chavez, Miguel A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vda8e0hdekh5nllcojocp22pm0